Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi
June 09, 2020 16:30 ET
|
Denali Therapeutics Inc.
Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b)Denali and Sanofi intend to accelerate DNL788 for...
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
May 27, 2020 16:30 ET
|
Denali Therapeutics Inc.
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with DNL310 (ETV:IDS), the...
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
May 07, 2020 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the...
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
April 02, 2020 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
February 27, 2020 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 31, 2020 20:41 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000 shares of...
Denali Therapeutics Announces Pricing of Public Offering of Common Stock
January 28, 2020 20:58 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its...
Denali Therapeutics Announces Proposed Offering of Common Stock
January 27, 2020 16:10 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell shares of its common stock in an underwritten...
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
January 14, 2020 09:00 ET
|
Denali Therapeutics Inc.
LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease LRRK2 inhibitor DNL151 Phase 1...
Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
November 06, 2019 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...